Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) and Arvinas (NASDAQ:ARVN – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.
Risk and Volatility
Monte Rosa Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.
Profitability
This table compares Monte Rosa Therapeutics and Arvinas’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Monte Rosa Therapeutics | -560.85% | -43.31% | -27.59% |
| Arvinas | 2.94% | 1.91% | 1.29% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Monte Rosa Therapeutics | $123.67 million | 9.71 | -$38.63 million | ($1.76) | -7.99 |
| Arvinas | $262.60 million | 2.08 | -$80.80 million | $0.10 | 84.50 |
Monte Rosa Therapeutics has higher earnings, but lower revenue than Arvinas. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current recommendations for Monte Rosa Therapeutics and Arvinas, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Monte Rosa Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
| Arvinas | 2 | 4 | 5 | 0 | 2.27 |
Monte Rosa Therapeutics currently has a consensus price target of $28.50, indicating a potential upside of 102.56%. Arvinas has a consensus price target of $14.17, indicating a potential upside of 67.65%. Given Monte Rosa Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than Arvinas.
Insider and Institutional Ownership
80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Comparatively, 7.3% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Arvinas beats Monte Rosa Therapeutics on 9 of the 15 factors compared between the two stocks.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
About Arvinas
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
